SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating) major shareholder Orbimed Advisors Llc sold 153,897 shares of the company's stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $31.96, for a total value of $4,918,548.12. Following the sale, the insider now owns 5,599,842 shares in the company, valued at approximately $178,970,950.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

SpringWorks Therapeutics Price Performance

SWTX stock opened at $30.42 on Friday. The company has a fifty day moving average price of $29.15 and a two-hundred day moving average price of $37.48. SpringWorks Therapeutics, Inc. has a one year low of $13.60 and a one year high of $77.70. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -6.53 and a beta of 0.85.

SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.15). During the same period in the previous year, the company earned ($0.97) EPS. The firm's revenue for the quarter was up .0% on a year-over-year basis. Research analysts anticipate that SpringWorks Therapeutics, Inc. will post -5.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Institutional Investors Weigh In On SpringWorks Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Parallel Advisors LLC lifted its holdings in shares of SpringWorks Therapeutics by 34.7% during the first quarter. Parallel Advisors LLC now owns 1,028 shares of the company's stock worth $61,000 after buying an additional 265 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in SpringWorks Therapeutics by 8.1% in the 1st quarter. Teacher Retirement System of Texas now owns 4,099 shares of the company's stock valued at $231,000 after purchasing an additional 307 shares during the period. Royal Bank of Canada boosted its holdings in SpringWorks Therapeutics by 1.8% in the 1st quarter. Royal Bank of Canada now owns 26,465 shares of the company's stock valued at $1,494,000 after purchasing an additional 479 shares during the period. US Bancorp DE boosted its holdings in SpringWorks Therapeutics by 20.7% in the 2nd quarter. US Bancorp DE now owns 3,246 shares of the company's stock valued at $80,000 after purchasing an additional 556 shares during the period. Finally, Credit Suisse AG boosted its holdings in SpringWorks Therapeutics by 3.0% in the 2nd quarter. Credit Suisse AG now owns 19,510 shares of the company's stock valued at $480,000 after purchasing an additional 566 shares during the period.

About SpringWorks Therapeutics

(Get Rating)

SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.

See Also

• Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
• No One Told These 3 Stocks It's a Down Week
• Is There a Cure for What is Ailing Teladoc Stock?
• Why Medical Products Maker Repligen May Be A Potential Buy
• At 10%, Is Arbor Realty Trust Dividend Worth It?
• Investors Should Tune Into RF Industries

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.